The increase in intensive treatment for cancer has impacted blood product transfusion practices. Transfusion guidelines are primarily institution specific, but the general concepts and theories are universal. Blood product screening has decreased the risk of transfusion-acquired infections; however, the risk is not obsolete. This article reviews current approaches to platelet, white blood cell, and red blood cell transfusions, as well as risks associated with these therapies (e.g., infection and transfusion-associated graft-versus-host dis ease). Pertinent laboratory studies, patient assessment, blood product adminis tration, and patient education is discussed. The current approaches to platelet, white blood cell, and red blood cell transfusions are constantly changed and evaluated. Pediatric oncology nurses must stay up to date with these changes to provide optimal patient care.
Get full access to this article
View all access options for this article.
References
1.
Beutler E. (1993). Platelet transfusions: The 20,000/μL trigger. Blood, 81, 1411-1413.
2.
Bodey G.P., Buckley M., Sathe Y.S., & Freireich E.J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals Internal Medicine, 64, 328-340.
3.
Bowden R.A., Slichter S.J. , Sayers M., Weisdorf D., Cays M., Schoch G., Banaji M., Haake R., Welk K., Fisher L., McCullough J., & Miller W. ( 1995). A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 86, 3598-3603.
4.
Cahill M.R., & Lilleyman J.S. (1998). The rationale use of platelet transfusions in children. Seminars in Thrombosis and Hemostasis , 24, 567-575.
5.
Camitta B., Chusid M.J., Starshak R.J., & Gottschall J.L. (1994). Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella. The Journal of Pediatrics, 124, 593-596.
6.
DeCoteau J., Haddad S., Blanchette V., & Poon A. (1995). Refractoriness to platelet transfusions in children with acute leukemia. Journal of Pediatric Hematology/Oncology, 17(4), 306-310.
7.
Dutcher J.P., Kendall J. , Norris D., Schiffer C., Aisner J., & Wiernik P.H. (1989). Granulocyte transfusion therapy and Amphotericin B: Adverse reactions?American Journal of Hematology, 31, 102-108.
8.
Dutcher J.P., Schiffer C.A. , Aisner J., & Wiernik P.H. ( 1981 a). Alloimmunization following platelet transfusion : the absence of a dose-response relationship . Blood, 57, 395-398.
9.
Dutcher J.P., Schiffer C.A. , Aisner J., & Wiernik P.H. (1981b). Long-term follow-up patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood, 58, 1007-1011.
10.
Freireich E.J. (1993). White cell transfusions born again. Leukemia and Lymphoma, 11(S2), 161-165.
11.
Freireich E.J., Judson G. , & Levin R.H. (1965 ). Separation and collection of leukocytes. Cancer Research, 25, 1516-1520.
12.
Freireich E.J., Morse E.E. , Bronson W., & Carbone P.P. (1962). Transfusion of granulocytes from donors with chronic myelocytic leukemia to leukopenic patients. Proceedings IXth Congress International Society Hematology, 1, 549-557.
13.
Gaydos L.A., Freireich E.J. , & Mantel N. (1962 ). The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. The New England Journal of Medicine, 266(18), 905-909.
14.
Genetic Drug Institute. (1997). Neumega® drug insert. Cambridge, MA. Author.
15.
Gleeson C., & Spencer D. (1995). Blood transfusion and its benefits in palliative care. Palliative Medicine, 9, 307-313.
16.
Gmur J., Burger J., Schanz U., Fehr J., & Schaffner A. (1991). Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. The Lancet, 338, 1223-1226.
17.
Greenberg, P., Goodrich, J., & Riddell, S. ( 1991). Adoptive immunotherapy of human cytomegalovirus infection: Potential role in protection from disease progression. Transplantation Proceedings, 23, 97-101.
18.
Hromas R., Cornetta K., Srour E., Blanke C. & Broun, E.R. (1994). Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T cell depleted bone marrow transplantation. Blood, 84, 1689-1690.
19.
Hume H.A., Kronick J.B., & Blanchette V.S. (1997). Review of the literature on allogeneic red blood cell and plasma transfusions in children. Canadian Medical Association Journal, 156, 541-549.
20.
Kolb H., Mittermuller J. , Clemm C., Holler E., Ledderose G., Brehm G., Heim M., & Wilmanns W. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-2465.
21.
Kolb H., Schattenberg A. , Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljuringman P. , Ferrant A., Verdonck L., Neirderwieser D., Rhee R., Mittermüller J. , de Witte T., Holler E., & Ansari H. ( 1995). Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
22.
Larsson S., Söderberg-Nauclér C.N., Wang F.-Z., & Möller E. (1998). Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion, 38, 271-278.
23.
Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F., Castro-Malaspina H., Childs B.H., Gillio A.P., Kernan N.A., Small T.A., Young J.W., & O'Reilly R.J. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation separating of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, 1261-1268.
24.
McCredie K.B., Freireich E.J., Hester J.P., Vallejos C. (1974). Increased granulocyte collection with the blood cell separator and the addition of etiocholanolone and hydroxyethyl starch. Transfusion, 14 (4), 357-364.
25.
McCredie K.B., Hersh E.M. , & Freireich E.J. ( 1971). Cells capable of colony formation in the peripheral blood of man. Science, 171(968), 293-294.
26.
Meyers J.D., Flournoy N. , & Thomas E.D. ( 1986). Risk factors for cytomegalovirus infection after human marrow transplantation. Journal of Infectious Disease, 153, 478-488.
27.
Micromedex Health Care Series (2000). Vol. 103. Englewood, CO: Micromedex, Inc.
28.
Narvios A.B., Przepiorka D., Tarrand J., Chan K-W., Champlin R., & Lichtiger B. (1998). Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplantation , 22, 575-577.
29.
National Blood Resource Education Program's Nursing Education Working Group. (1991). Transfusion nursing : Trends and practices for the 90s. Choosing blood components and equipment . American Journal of Nursing, 91, 42-52.
30.
National Institutes of Health. (1987). Consensus development conference on platelet transfusion therapy. JAMA, 257, 1777-1780.
31.
Naughton M. (1998). Biologic response modifiers. In M.J. Hockenberry-Eaton (Ed.), Essentials of pediatric oncology nursing (pp 110-112). Glenview, IL: Association of Pediatric Oncology Nurses .
32.
Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H., Castro-Malaspina H., Childs B.H., Gillio A.P., Small T.A., Young J.W., Kernan N.A., & O'Reilly J. (1994). Infusions of donor leukocytes to treat epstein-barr-virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. The New England Journal of Medicine, 330, 1185-1191.
33.
Pisciotto P.T. (1993). Blood transfusion therapy: A physician's handbook (4th ed.). Bethesda, MD. American Association of Blood Banks.
34.
Porter D.L., Roth M.S., Lee S.J., McGarigle C., Ferrara J.L.M., & Antin J.H. (1996). Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplantation , 18, 975-980.
35.
Rebulla P., Finazzi G., Marangoni F., Avvisati G. , Gugliotta L., Tognoni G., Barbui T., Mandelli F., & Sirchia G. For the Gruppo Italiano Malattie. Ematologiche Maligne Dell Adulto. (1997). The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. The New England Journal of Medicine, 337(26), 1870-1875.
36.
Riddell S.R., & Greenberg P.D. (1990). The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells . Journal of Immunological Methods, 128(2), 189-201.
37.
Riddell S.R., Reusser P. , & Greenberg P.D. ( 1991). Cytotoxic T cells specific for cytomegalovirus: Potential therapy for immunocompromised patients. Reviews of Infectious Disease, 13, S966-73.
38.
Riddell S.R., Watanabe K.S. , Goodrich J.M., Li C.R., Agha M.E., & Greenberg P.D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science, 257, 238-241.
39.
Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., Brenner M.K., & Hesiop H.E. (1995). Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-Virus-related lymphoproliferation. The Lancet, 345, 9-13.
40.
Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K. , Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A. , Brenner M.K., & Heslop H.E. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr Virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
41.
Rust D.M., Wood L.S., & Battiato L.A. (1999). Oprelvekin: An alternative treatment for thrombocytopenia. Clinical Journal of Oncology Nursing, 3(2), 57-62.
42.
Saarinen U.M., Hovi L., Vilinikka L., Juvonen E. , & Myllyla G. ( 1995). Reemphasis on leukocyte transfusions : induction of myeloid marrow recovery in critically ill neutropenic children with cancer. Vox Sanguinis, 68 (2),90-99.
43.
Saarinen U.M., Kekomaki R. , Siimes M.A., & Myllyla G. (1990). Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood, 75, 512-517.
44.
Slichter S.J., Corash L. , Schiffer C.A., & Kickler T. (1996). Transfusion Medicine: Newer approaches to platelet transfusion therapy. Hematology: Education Program American Society of Hematology, 119-131.
Sniecinski I., O'Donnell M.R., Nowicki B., & Hill L.R. (1988). Prevention of refractoriness and HLA-Alloimmunization using filtered blood products. Blood, 71, 1402-1407.
47.
The Trial to Reduce Alloimmunization to Platelets (TRAP) Study Group. (1997). Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine , 337(26), 1861-1869.
48.
U.S. Department of Health and Human Services. ( 1990). Transfusion therapy guidelines for nurses. (NIH Publication No. 90-2668a. Bethesda, MD: Author .
49.
Voak D. (Chairman), BCSH Blood Transfusion Task Force. Membership: Chapman J., Finney R.D., Forman K., Kelsey P., Knowles S.M., Napier J.A.F., Phillips P. , Mitchell R., Murphy M.F., Waters A.H., Wood J.K., Williamson L.M. , Baglin T., Copplestone A., Dendy P., Forman K., Gibson B., Knowles S., Morgan G., Norfolk D., Richards A. , Todd A., Warwick R., & Webb D. ( 1996). Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine, 6, 261-271.
50.
Wallace E.L., Churchill W.H. , Surgenor D.M., Cho G.S., & McGurk S. ( 1998). Collection and transfusion of blood and blood components in the United States, 1994. Transfusion, 38, 625-635.
51.
Walter E.A., Greenberg P.D. , Gilbert M.J., Finch R.J., Watanabe K.E., Thomas E.D., & Riddell S.R. (1995).
52.
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from donor. The New England Journal of Medicine, 333, 1038-1044.
53.
Walter-Coleman S. (1996). Transfusion therapy for patients critically ill with cancer. American Association of Critical Care Nurses, 7(1), 37-45.
54.
Wandt H., Frank M., Ehninger G., Schneider C. , Brack N., Daoud A., Schwalbe I., Fischer J., Gackle R., Geer T., Harms P., Loffler B., Ohl S., Otremba B., Raab M., Nabulsi P., Strobel G., Winter R., & Link H. (1998).
55.
Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 109/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood, 91, 3601-3606.
56.
Welte K., Gabrilove J., Bronchud M.H., Platzer E. , & Morstyn G. ( 1996). Filgrastim: The first 10 years. Blood , 88, 1907-1929.
57.
Wilkinson S.L., & Lipton K.S. (1999). NAT Implementation (Association Bulletin #99-3. Bethesda, MD: American Association of Blood Banks.
58.
Woolery-Antill M., & Colter C. (1993). Biologic response modifiers . In G.V. Foley, D. Fochtman, & K. Hardin Mooney (Eds.), Nursing care of the child with cancer (pp 179-207). Philadelphia, PA. W.B. Saunders.
59.
Worrall L.M., Tompkins C.A. , & Rust M. (1999 ). Recognizing and managing anemia. Clinical Journal of Oncology Nursing, 3, 153-160.
60.
Wuest D.L. (1996). Transfusion and stem cell support in cancer treatment. Hematology/Oncology Clinics of North America, 10(2), 397-429.
